Apimeds Pharmaceuticals US, Inc. (APUS) — Strategic Asset Allocation Index
Apimeds Pharmaceuticals US, Inc. (APUS) has a Strategic Asset Allocation Index of 101.0% as of March 2026. Strategic assets (PP&E of $- plus long-term investments of $127.82 Million) total $127.82 Million, measured against net assets of $126.52 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check APUS tangible net assets ratio to evaluate the tangible quality of the company's equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Apimeds Pharmaceuticals US, Inc. Strategic Asset Allocation Index (2025–2025)
This chart shows how Apimeds Pharmaceuticals US, Inc.'s Strategic Asset Allocation Index has evolved across 1 annual periods from 2025 to 2025. As of March 2026, the index stands at 101.0%, representing strategic assets of $127.82 Million against net assets of $126.52 Million USD.
Annual Strategic Asset Allocation Index for Apimeds Pharmaceuticals US, Inc. (2025–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for Apimeds Pharmaceuticals US, Inc. from 2025 to 2025, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Apimeds Pharmaceuticals US, Inc. market cap and net worth.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 97.7% | $149.89 Million | $- | $149.89 Million | $153.35 Million | — |